Przejdź do zawartości
Merck

Mitochondrial B-oxidation of adipose-derived fatty acids by osteoblast fuels parathyroid hormone-induced bone formation.

JCI insight (2023-02-03)
Nathalie Alekos, Priyanka Kushwaha, Soohyun Kim, Zhu Li, Abdullah Abood, Naomi Dirckx, Susan Aja, Joe Kodama, Jean Garcia-Diaz, Satoru Otsuru, Elizabeth Rendina-Ruedy, Michael J Wolfgang, Ryan C Riddle
ABSTRAKT

The energetic costs of bone formation require osteoblasts to coordinate their activities with tissues, like adipose, that can supply energy-dense macronutrients. In the case of intermittent parathyroid hormone treatment (PTH), a strategy used to reduce fracture risk, bone formation is proceeded by a change in systemic lipid homeostasis. To investigate the requirement for fatty acid oxidation by osteoblasts during PTH-induced bone formation, we subjected mice with osteoblast-specific deficiency of mitochondrial long-chain β-oxidation as well as mice with adipocyte-specific deficiency for the PTH receptor or adipose triglyceride lipase to an anabolic treatment regime. PTH increased the release of fatty acids from adipocytes and B-oxidation by osteoblasts, while the genetic mouse models were resistant to the hormone's anabolic effect. Collectively, these data suggest that PTH's anabolic actions requires coordinated signaling between bone and adipose, wherein a lipolytic response liberates fatty acids that are oxidized by osteoblasts to fuel bone formation.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Anti-PTH/PTHrP Receptor Antibody, clone 3D1.1, clone 3D1.1, Upstate®, from mouse